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Abstract 
Due to the growing number of Helicobacter pylori strains resistant to currently available antibiotics, there is an urgent need to design 
new drugs utilizing different molecular mechanisms than those that have been used up to now. Enzymes of the purine salvage pathway 
are possible targets of such new antibiotics because H. pylori is not able to synthetize purine nucleotides de novo. The bacterium’s 
recovery of purines and purine nucleotides from the environment is the only source of these essential DNA and RNA building blocks. 
We have identified formycins and hadacidin as potent inhibitors of purine nucleoside phosphorylase (PNP) and adenylosuccinate 
synthetase (AdSS) from H. pylori — two key enzymes of the purine salvage pathway. However, we have found that these compounds 
are not effective in H. pylori cell cultures. To address this issue, we have developed a universal comprehensive method for assessing H. 
pylori cell penetration by drug candidates, with three alternative detection assays. These include liquid chromatography tandem mass 
spectrometry, UV absorption, and inhibition of the target enzyme by the tested compound. Using this approach, we have shown that 
cellular uptake by H. pylori of formycins and hadacidin is very poor, which reveals why their in vitro inhibition of PNP and AdSS and 
their effect on H. pylori cell cultures are so different. The cell penetration assessment method developed here will be extremely useful 
for validating the cellular uptake of other drug candidates, facilitating the design of new potent therapeutic agents against H. pylori.
Key points 
• A method for assessing H. pylori cells penetration by drug candidates is described.
• Three alternative detection assays that complement each other can be used.
• The method may be adapted for other bacteria as well.
Keywords Helicobacter pylori · Cells penetration by drug candidates · Salvage pathway enzymes · Formycin · Hadacidin
Introduction
The gram-negative microaerophilic bacterium Helico-
bacter pylori is a common pathogen affecting about 
50% of the human population worldwide (Kamboj 
et al. 2017). Since its identification by Marshall and 
Warren (1984), H. pylori is seen as a serious threat to 
human health, through its involvement in the devel-
opment of diseases such as chronic active gastritis, 
peptic ulceration, gastric adenocarcinoma, and gastric 
mucosa-associated lymphoid tissue lymphoma (Abadi 
2017). In 1994 it was classified as a class I human 
carcinogen (Humans 1994; Miftahussurur et al. 2017).
Various therapies are currently used and recommended 
for eradication of H. pylori. The fact that there are so 
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many of them is because none of them is universal and 
effective in all circumstances and in every region of the 
world. It is estimated that treatment for H. pylori fails 
in more than 20% of patients (Roszczenko-Jasińska 
et al. 2020). One of the most popular is a standard 
triple 10–14 days therapy consisting of a proton pump 
inhibitor, amoxicillin and clarithromycin or metroni-
dazole (Suzuki and Mori 2018). However, with the 
growing resistance of H. pylori to antimicrobial agents, 
especially to clarithromycin and metronidazole, in the 
triple therapy, these antibiotics are often replaced 
by other drugs, e.g., by levofloxacin, sitafloxacin, or 
rifabutin (Thung et al. 2016; Suzuki and Mori 2018). 
Unfortunately, even with these modifications, stand-
ard triple therapy is no longer effective in most coun-
tries (Huang et al. 2017). Alternative approaches were 
therefore proposed including high-dose dual, bismuth 
quadruple and non-bismuth quadruple therapies, the 
latter one with several variants like sequential, con-
comitant, hybrid, and reverse hybrid. High-dose dual 
therapy consists of high-dose proton pump inhibi-
tor and amoxicillin, as they are administrated for 14 
days but four times per day (Huang et al. 2017). The 
2016 Maastricht V/Florence Consensus Report (Mal-
fertheiner et al. 2017) and the 2016 Toronto Consensus 
(Fallone et al. 2016) recommended a bismuth quad-
ruple therapy as a first-line choice, especially when 
resistance to clarithromycin occurs. This treatment 
includes a proton pump inhibitor, bismuth, metroni-
dazole, and tetracycline; is well tolerated by patients; 
and shows effectiveness even against in vitro metroni-
dazole-resistant strains. If bismuth is not available, a 
concomitant quadruple therapy may be used, consist-
ing of a proton pump inhibitor, amoxicillin, metronida-
zole, and clarithromycin (Kamboj et al. 2017; Fallone 
et al. 2019; Matsumoto et al. 2019; Suzuki et al. 2019). 
In a sequential therapy, a proton pump inhibitor and 
amoxicillin is administrated for the first half of the 
treatment (5 days), with metronidazole or clarithromy-
cin replacing amoxicillin for the second half (Kamboj 
et al. 2017). In the hybrid or reverse hybrid therapy, 
a proton pump inhibitor and amoxicillin are admin-
istrated for 10–14 days, while metronidazole and 
clarithromycin only for the first and the second half, 
respectively (Huang et al. 2017).
However, given the generally increased use of antibiotics, 
the burden of resistant strains of H. pylori is also expected 
to rise (Kuo et al. 2021; Megraud et al., 2021). Therefore, 
the search for novel targets for drugs against H. pylori, with 
different mechanisms of action, is of utmost importance 
(Roszczenko-Jasińska et al. 2020). High effort in this area 
resulted in various novel therapeutic regiments that should 
improve eradication rate achieved by standard therapies and 
should restrict the increase of antibiotic-resistant bacteria. 
These are for example probiotics, plant extracts, or inhibitors 
of biofilm formation (Roszczenko-Jasińska et al. 2020). Nev-
ertheless, new approaches that can serve as a replacement 
for current therapies are necessary. When the genome of 
H. pylori was published (Tomb et al. 1997), it opened pos-
sibilities for studying the physiology of this pathogen (Doig 
et al. 1999) in order to identify promising new drug targets. 
Analysis showed that many redundant metabolic pathways 
are missing in this bacterium, among them the pathway of 
de novo purine nucleotides synthesis (Hazell and Mendz 
1997). Therefore, H. pylori relies exclusively on the purine 
nucleotide cycle, the so-called purine salvage pathway, for 
acquisition of purine nucleotides, which are the indispensa-
ble building blocks of DNA and RNA. This prompted us to 
study proteins involved in the purine salvage pathway of this 
bacterium as possible targets for new antibiotics, as has been 
done with parasitic protozoa (El Kouni 2003), e.g., the Plas-
modium responsible for malaria (e.g., Ducati et al. 2013).
Recently published results of Dziekan et al. (2019) have 
brought additional proof that enzymes of purine salvage 
pathway may be promising drug targets. They studied qui-
nine and mefloquine, two important antimalarial drugs with 
poorly characterized mechanisms of action. Using the cellu-
lar thermal shift assay coupled with mass spectrometry, they 
showed that in Plasmodium falciparum, purine nucleoside 
phosphorylase (PNP, E.C. 2.4.2.1) is a common binding target 
for these two quinoline drugs. Additionally employing bio-
physical structural studies, the authors have shown that both 
compounds bind within the enzyme’s active site. Moreover, 
in solution studies, it was demonstrated that quinine binds to 
P. falciparum PNP with low nanomolar affinity, suggesting a 
significant role of this interaction in the therapeutic effect of 
the drug. PNP is a key enzyme of the purine salvage pathway 
(Fig. 1b), as it catalyzes the reversible phosphorolytic cleavage 
of the glycosidic bond of purine ribo- and deoxyribonucleo-
sides, inosine, adenosine, and guanosine, as follows: (deoxy)
purine nucleoside + orthophosphate → purine base + (deoxy)
ribose-1-phosphate.
Using the well-characterized Escherichia coli purine nucleo-
side biosynthesis pathway as a template, Liechti and Goldberg 
(2012) generated mutants of H. pylori with deletions of genes 
for numerous putative purine nucleoside salvage pathway ele-
ments — among them deoD and purA genes encoding for 
PNP and adenylosuccinate synthetase (AdSS), respectively. 
AdSS (E.C. 6.3.4.4) catalyzes the first step in the biosynthe-
sis of AMP from IMP (Fig. 1b), generating adenylosuccinate, 
as follows: IMP + aspartate + GTP  (Mg2+) → adenylosucci-
nate + GDP + orthophosphate. In the second step, adenylosucci-
nate lyase cleaves adenylosuccinate to form AMP. AdSS operates 
at a branch point of the purine salvage pathway and the de novo 
synthesis of purines (Fig. 1a, b).
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Liechti and Goldberg (2012) found that a ΔpurA mutant 
(missing the gene encoding for adenylosuccinate synthetase, 
AdSS) is capable of growth only in medium supplemented 
with adenine or adenosine, and that its growth is signifi-
cantly retarded in nutrient-rich medium. The data indicate 
the essentiality of AdSS for survival of H. pylori. In contrast, 
deletion of the putative nucleoside phosphorylase (PNP) 
gene, deoD, resulted in an inability of H. pylori to grow on 
purine nucleosides or the purine base adenine. These results 
suggest that inhibiting these two enzymes, PNP and AdSS, 
may cause an additive, or even a synergistic, effect in H. 
pylori (Pillai et al. 2005).
Given the importance of purine production and its 
direct effect on bacterial growth rates, and taking into 
account all aspects raised above, targeting enzymes of 
the salvage pathway seems to be a promising approach 
for therapy against H. pylori. The main objectives of the 
current project, which we initiated some time ago, are 
to understand molecular mechanisms of these two key 
enzymes, PNP and AdSS of the purine salvage pathway 
of this bacterium, and ascertain whether this knowledge 
may be useful to eradicate H. pylori using newly designed 
drugs. We have already described catalytic properties of 
H. pylori purine nucleoside phosphorylase, identified 
(a)
(b)
Fig. 1  The purine nucleotide biosynthesis pathway in H. pylori. 
(a) De novo purine nucleotide biosynthetic pathway functioning in 
E. coli. Homologs for genes required for this pathway found in H. 
pylori are shown in black, while all enzymes for which homologs 
were not found in the H. pylori genome are marked in gray. (b) 
Purine salvage pathway in H. pylori; purine rings, shown in the 
bottom row, are obtained from environment. Enzymes that have 
been studied in H. pylori by mutant analysis and/or biochemis-
try are shown in violet. Enzymes described in this work, purine 
nucleoside phosphorylase (PunB, PNP) and adenylosuccinate syn-
thetase (PurA, AdSS), are shown in red frames. Enzymes with 
likely function, but whose genes have not yet been identified are 
shown in green (figure adapted from Jenkins et  al. 2011, Liechti 
and Goldberg 2012, Miller et  al. 2012). Abbreviations: PRPP, 
5-phosphoribosyl diphosphate; GAR, glycinamide ribonucleotide; 
FGAR, N-formylglycinamide ribonucleotide; FGAM, 5′-phospho-
ribosylformylglycinamidine; AIR, aminoimidazole ribotide; CAIR, 
5′-phosphoribosyl-4-carboxy-5-aminoimidazole; SAICAR, 5′-phos-
phoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole; AICAR, 
5-aminoimidazole-4-carboxamide ribotide; FIACAR, 5′-phospho-
ribosyl-5-formamido-4-imidazolecarboxamide; PurF, amidophos-
phoribosyltransferase; PurD, phosphoribosylamine-glycine ligase; 
PurN, phosphoribosylglycinamide formyltransferase; PurL, phos-
phoribosylformylglycinamidine synthase; PurM, phosphoribosylfor-
mylglycinamidine cyclo-ligase; PurK, N5-carboxyaminoimidazole 
ribonucleotide synthase; PurE, N5-carboxyaminoimidazole ribonu-
cleotide mutase; PurC, phosphoribosylaminoimidazole-succinocar-
boxamide synthase; PurH, bifunctional purine biosynthesis protein 
PurH; GuaB, IMP dehydrogenase; GuaA, GMP synthetase; GuaC, 
GMP reductase; PurA, adenylosuccinate synthetase; PurB, ade-
nylosuccinate lyase; Gpt, hypoxanthine–guanine phosphoribosyl-
transferase; Apt, adenine phosphoribosyltransferase; SurE, 5′-nucle-
otidase; PunB (deoD gene), purine nucleoside phosphorylase; 
Ade, adenine deaminase; Add, adenosine deaminase; IMP, inosine 
monophosphate; XMP, xanthosine monophosphate; GMP, guano-
sine monophosphate; AMP, adenosine monophosphate
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potent inhibitors, and obtained the 3D structure of this 
enzyme complexed with one of its nucleoside inhibitors, 
formycin A (see Fig. 2) (Narczyk et al. 2018). Simulta-
neously, we have obtained recombinant H. pylori adeny-
losuccinate synthetase and characterized its biochemical 
and kinetic properties (Bubić et al. 2018), and recently 
we have also determined the 3D structure of this enzyme 
in a complex with its potent inhibitor, hadacidin (Fig. 2) 
(unpublished, PDB 6ZXQ).
In the present manuscript, we report properties of one 
more nucleoside PNP inhibitor, formycin B; the effects 
of all three compounds, formycin A, formycin B, and 
hadacidin, on H. pylori growth as determined by their 
minimal inhibitory concentrations, MIC; and the pos-
sible synergy of PNP and AdSS inhibitors, as evaluated 
by the fractional inhibitory concentration index (FICI) 
(Pillai et al, 2005). To understand reasons for discrepan-
cies between observed effects in vivo and in vitro, we 
have measured the cellular uptake of these inhibitors. 
To that end we developed, based on Zhou et al. (2015), 
a universal method suitable a priori for checking bacte-
rial cellular uptake of any possible inhibitor, not only 
radiolabeled or fluorescently labeled compounds. This 
method will be extremely useful in further studies of cel-
lular penetration of any inhibitor of H. pylori enzymes, 
not only those belonging to the purine salvage pathway, 
and the method may also be adapted to study cellular 
uptake of drugs by any other bacteria.
Materials and methods
Materials
Metronidazole (MW 171.15 g/mol), inosine 5′-monopho-
shate disodium salt hydrate (IMP, MW 392.17 g/mol), 
guanosine 5′-triphosphate sodium salt hydrate (GTP, MW 
523.18 g/mol), L-aspartic acid sodium salt monohydrate 
(MW 173.10 g/mol), L-arginine-5-13C,4,4,5,5-d4 (MW 
179.22 g/mol), magnesium chloride, amoxicillin, and Nutri-
ent Mixture F12 Ham medium were obtained from Sigma-
Aldrich (Saint Louis, MO, USA). Formycin A (monohy-
drate, MW 285.27 g/mol) and formycin B (MW 268.23 g/
mol) were purchased from Berry & Associates (Dexter, MI, 
USA). Hadacidin (MW 119.08 g/mol) was purchased from 
Anji Biosciences (Hyderabad, India). 7-Methylguanosine 
 (m7Guo) was synthesized from guanosine according to 
Jones and Robins (1963) using the method involving methyl 
iodide. This yields preparation free of sulfate, which as an 
ion resembling phosphate, a purine nucleoside phosphory-
lase substrate, could bias the results. Partition coefficients 
between the lipid and aqueous phases of the neutral, log P, 
and ionized, log D, forms of the tested compounds, and of 
metronidazole used as a control in the cellular uptake stud-
ies, were calculated using the Molinspiration Cheminfor-
matics website http:// www. molin spira tion. com.
Recombinant purine nucleoside phosphorylase (PNP) 





































Fig. 2  Inhibitors studied in this report, formycins A and B, hadaci-
din and metronidazole. Formycins A and B are structural analogues 
of natural PNP substrates, adenosine and inosine, respectively, with 
the C–C bond linking purine base and the sugar moiety, instead of 
the N–C glycosidic bond present in adenosine and inosine. Note the 
difference in base ring numbering of formycins when compared with 
purine ring numbering. In contrast to natural PNP substrates, adeno-
sine, inosine, and guanosine, formycins may exist in more than one 
tautomeric form. Here the structure of N(1)-H tautomer is shown 
(Wierzchowski and Shugar 1982; Bzowska et  al. 1992). Hadacidin 
is a structural analogue of one of the AdSS substrates, aspartate, and 
is a potent inhibitor of this enzyme (Iancu et  al. 2006; Bubić et  al. 
2018). Metronidazole is an antibiotic efficiently used in therapy 
against H. pylori (e.g., Min Kim et al.; Olmedo et al. 2020), and it is 
used in this study as a positive control of the cellular uptake
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26695 strain were obtained as described previously (Bubić 
et al. 2018; Narczyk et al. 2018).
Culture reagents Fetal Bovine Serum, Helicobacter pylori 
Selective Supplement, Brain Heart Infusion Broth (BHI 
medium) and horse serum (5%), New Zealand Origin, heat 
inactivated, were from Thermo Fisher Scientific (Waltham, 
MA, USA). Yeast extract (2.5%) and Christensen’s urea 
broth were from Torlak (Serbia) and BD IsoVitaleX (1%) 
from Becton, Dickinson and Company (Franklin Lakes, 
NJ, USA).
Atmosphere generators were purchased from Biomerieux, 
France, and from Mart Microbiology B.V., The Netherlands 
(Anoxomat Mark II). 24-deep-well 2 mL plates, flat-bot-
tomed for suspension cultures used to evaluate H. pylori 
growth under various conditions, were from Nest Scientific 
Biotechnology (NJ, USA). The H. pylori wild-type strain 
26695 was obtained from ATCC (Manassas, VA, USA), 
while the SS1 strain was a mouse-adapted H. pylori isolated 
from a patient with peptic ulcer disease (Touati et al. 2000).
Inhibition constant for formycin B vs. H. pylori PNP
The inhibition constant for formycin B vs. 26695 H. pylori 
strain PNP was determined at 25 °C, in 50 mM Hepes/NaOH 
pH 7.0, 50 mM phosphate, with  m7Guo as a variable sub-
strate, using the initial velocity method and spectrophotomet-
ric assay at λobs = 260 nm, as described earlier for inhibition 
constant of formycin A vs. the same enzyme (Narczyk et al. 
2018). Kinetic experiments with PNP, and also with AdSS, 
described in the section “AdSS and PNP inhibition detection 
of cellular uptake”, were performed on a double-beam UV/
VIS spectrophotometer Cary 100, with thermostated Peltier 
cell holders (Varian: Agilent Technologies, Mulgrave, Vic., 
Australia). The inhibition constant was determined as the 
adjustable parameter in the global fitting of the competitive 
inhibition model to all data obtained, using the GraphPad 
Prism program (GraphPad Software, San Diego, CA, USA).
Minimal inhibitory concentration (MIC)
Minimal inhibitory concentration of inhibitors was deter-
mined by an in vitro broth microdilution assay (Knezevic 
et al. 2018). Briefly, double-strength Brain heart infusion 
broth (BHI) was supplemented with yeast extract (2.5%), 
horse serum (5%), and IsoVitaleX (1%). In each well, two-
fold serial dilutions of inhibitors (from 1000 µg/mL to 
7.8 μg/mL in a final volume) and an equal volume of inocu-
lated double-strength BHI were added (approx. 1 ×  106 CFU/
mL in final volume). Amoxicillin was used as a positive 
control, and distilled water as a negative control. The micr-
otiter plates were incubated at 37 °C under microaerobic 
conditions in moist atmosphere for 3 days. For easier MIC 
determination, the method was improved by addition of the 
equal volumes of double-strength Christensen’s urea broth 
into wells after incubation, and the plates were additionally 
incubated 4 h in an aerobic atmosphere at 37 °C. During the 
incubation, in wells with viable H. pylori urease produced by 
the bacteria converted urea into ammonia and carbon diox-
ide, changing the pH and color of a phenol red indicator in 
the medium (from orange to purple). The plates were exam-
ined visually for color change and  OD560 was measured after 
4 h in order to determine presence/absence of growth. The 
MIC is defined as the lowest concentration of a compound 
that inhibits visible growth, compared with the growth in the 
controls (in this case defined as presence/absence of color 
change). All experiments were performed in duplicate and 
in 3–6 independent tests.
Inhibitor combinations
In order to determine possible additive or even synergis-
tic effect of inhibitors, a method with calculation of the 
fractional inhibitory concentration index (FICI) was used 
(Pillai et al, 2005). A combination of two inhibitors was 
applied (w/w 1:1) in the final concentration 1 mg/mL and 
subsequently diluted. The FICI index was calculated as 
FICI =  (MICA/MICa) +  (MICB/MICb), where  MICA = con-
centration of inhibitor a in combination with inhibitor b; 
MICa = MIC of inhibitor a, applied as a single agent; 
 MICB = concentration of inhibitor b in combination with 
inhibitor a; and MICb = MIC of inhibitor b applied as a sin-
gle agent. The results were interpreted as a synergistic effect 
if the FICI was ≤ 0.5; as an additive effect if 0.5 < FICI ≤ 1; 
an indifferent effect if 1 < FICI ≤ 4; and as an antagonistic 
effect if the FICI was > 4 (Pillai et al. 2005).
Cellular uptake experiments
Cellular uptake of PNP inhibitors, formycin A (FA) and 
formycin B (FB), and the control compound, metronidazole 
(MTZ), was determined using the approach described by 
Zhou et al. (2015) for E. coli and Pseudomonas aeruginosa, 
adapted to conditions suitable for H. pylori cell growth. This 
method measures the change of extracellular drug concentra-
tion using LC–MS detection. We also developed additional 
methods of detection, since LC–MS was not suitable for 
hadacidin (Hada) (see below).
Overnight cultures of H. pylori wild-type 26695 strain 
were grown by shaking (120 rpm) at 37 °C under microaero-
philic conditions (5%  O2, 10%  CO2, 85%  N2) in BHI medium 
(37 g/L) supplemented with 10% Fetal Bovine Serum and 
1% Helicobacter pylori Selective Supplement. Cells were 
collected by centrifugation (5 min at 8000 × g at room tem-
perature). The supernatant was decanted and the cell pel-
lets were suspended in F12 medium (with L-glutamine and 
sodium bicarbonate) and centrifuged again. The supernatant 
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was decanted again and cell pellets were resuspended in such 
a volume of F12 medium to obtain an  OD600 of 4.0. F12 
medium was selected for experiments because it is a minimal 
medium of defined composition and is suitable for measure-
ments on MS.
The accumulation test was carried out in 24-deep-well 
2 mL flat-bottomed plates, all in a final volume of 1 mL. 
Three types of samples were used, generated by mixing 
the following components in a 1:1 ratio: (1) concentrated 
and resuspended cells in F12 medium, (2) a solution of 
the appropriate concentration of a test compound in F12 
medium, (3) F12 medium. Mixing (1) and (2) gave the basic 
samples (named “Inhibitor + H. pylori cells”), while mixing 
(1) with (3), and (2) with (3), gave two types of the control 
samples, called “H. pylori cells” and “Inhibitor,” respec-
tively (Fig. 3).
The final concentration of the metronidazole, used as a posi-
tive control of the uptake process, was 0.5 µM (80 ng/mL); this 
is a 100-times lower concentration than the MIC value — mini-
mal inhibitory concentration (according to EUCAST 2020). The 
final concentrations of the tested compounds were 350 µM and 
35 µM for formycin A and formycin B, and 35 μM for hadaci-
din. One set of three replicate samples was incubated at 37 °C, 
and the other set was incubated at 4 °C. Samples were taken at 
the start of the accumulation test, to check the concentration 
of the inhibitor at the start (named “Inhibitor_start,” “H. 
pylori + inhibitor_start”), then after 4 and 8 h of incubation 
at both temperatures. The obtained samples were centrifuged 
at 8000 × g for 5 min at 4 °C. The supernatant was collected 
for the LC–MS analysis (used for MTZ, FA, and FB uptake), 
UV absorption measurements (used for FA and FB uptake), 
and AdSS and PNP inhibition analysis (used for Hada and FB 
uptake).
The samples incubated in the cold condition (4 °C) were 
included to account for nonspecific binding of tested com-
pounds to the surface of the bacterial cell wall.
The samples of the inhibitor in the F12 medium, without 
cells (“Inhibitor”) at both temperatures, were included to 
check solvent evaporation, compound degradation, and non-
specific binding of the compound to the plates.
The samples of the cells in the F12 medium, without 
inhibitor (“H. pylori cells”) at both temperatures, were 
included to check cellular uptake or release of some com-
pounds from or to the medium that may interfere with UV 
absorption and enzyme inhibition measurements.
The differences observed between the samples of the 
inhibitor, incubated with and without H. pylori cells, at 
cold 4 °C and warm 37 °C conditions, were used to estimate 
the intracellular accumulation of the tested compound, as 
described by Zhou et al. (2015):
Fig. 3  Graphical description 
of the inhibitor accumulation 
experiments. The key idea of 
the method is to measure the 
change of extracellular inhibitor 
concentration, after incubation 
of the compound in the presence 
of H. pylori cells, to estimate 
the intracellular accumulation 
of the tested compound. Quan-
tification of the extracellular 
concentration of inhibitors in 
the supernatants was done with 
the aid of one or more detection 
methods: ultra-performance 
liquid chromatography–tandem 
mass spectrometry, UV absorp-
tion measurement or determi-
nation of the inhibition of the 
target enzyme for the tested 
compound, as described in 
“Materials and methods” (based 
on Zhou et al. 2015)
H. pylori cell culture grown in rich medium
Cell pellet, resuspended in F12 medium to get OD600 ~ 4.0
Start of the uptake experiment
Inhibitor Inhibitor+H.pylori cells H.pylori cells
8h, 37oC 8h, 4oC
Centrifuge and collect supernatants
LC-MS LC-MS
Absorbance in UV Inhibion of the target enzyme
Inhibitor Inhibitor+H.pylori cells H.pylori cells Inhibitor Inhibitor+H.pylori cells H.pylori cells
7954 Applied Microbiology and Biotechnology (2021) 105:7949–7967
1 3
C corresponds to inhibitor concentration, and subscripts 
“inhibitor” and “Hp + inhibitor” refer to the control without 
cells and samples of the inhibitor incubated in the presence 
of H. pylori cells, respectively (see above), while subscript 
37 °C and 4 °C refer to two temperature conditions used.
This simple form of the equation was used for LC–MS 
detection, which is most specific of the three methods we 
used. For the UV absorption and inhibition of the target 
enzyme detection of the cellular uptake of tested inhibitors 
(see below), samples with H. pylori cells in F12 medium 
incubated for 4 and 8 h at both temperatures were also 
included (“H. pylori cells,” see above). These samples were 
necessary to make correction of the results for the effects 
caused by uptake of some nutrients from the medium by 
H. pylori cells, as well as by release of some metabolic 
products, which may exhibit absorption in UV–VIS range 
and may inhibit target enzyme. In these cases, Eq. (1) was 
extended to account for these effects and this is described in 
detail in next sections (see Eq. (5) below).
LC–MS detection of cellular uptake
Formycin A, formycin B, and metronidazole were quanti-
fied through the ultra-performance liquid chromatogra-
phy–tandem mass spectrometry. Samples were analyzed on 
Waters Xevo TQ-S with a standard ESI ion source coupled 
to Waters Acquity I-class UPLC.
Calibration samples were prepared by spiking blank 
growth medium F12 by the tested inhibitor, formycin A, 
formycin B, or metronidazole solutions. Internal standards 
(IS) were used to improve the accuracy of the method. To 
each pipetted sample from a particular experiment, the same 
amount of IS was added. As a detector response, we consid-
ered the ratio of the analyte peak area (variable) to the inter-
nal standard peak area (constant). This allows compensation 
for signal changes due to a possible instability of the ion 
source. If the ionization efficiency changes, both compounds 
are affected, but the surface peak ratio is maintained. As 
internal standards, compounds that do not occur naturally 
in H. pylori were used, namely formycin A, when analyzing 
formycin B, and vice versa, and deuterated arginine when 
metronidazole uptake was determined. Samples and calibra-
tors were precipitated using IS solution and injected on the 
instrument.
Calibration curves were acquired by plotting the concen-
tration of the standards against the ratio of the analyte peak 
area to the IS peak area. The calibration curve for FA in 
low concentration (35 μM) consisted of 7 samples in the 
(1)
Caccumulated intracellular
= (Cinhibitor8h37oC − C(Hp+inhibitor)8h37oC)
− (Cinhibitor8h4oC − C(Hp+inhibitor)8h4oC)
range from 0.23 to 37.5 μM (R2 = 0.997); for FA in high 
concentration (350 μM), the curve consisted of 6 samples in 
the range from 3.7 to 374.7 μM (R2 = 0.995); for FB in low 
concentration (35 μM), the curve consisted of 7 samples in 
the range from 0.291 to 46.5 μM (R2 = 0.999); for FB in high 
concentration (350 μM), the curve consisted of 7 samples in 
the range from 2.91 to 465.0 μM (R2 = 0.999); and for MTZ 
(0.5 μM), the calibration curve was 8 samples in the range 
from 0.584 to 584.2 nM (R2 = 0.995).
Chromatography was run on Waters Acquity BEH C18, 
1.7 μm, 2.1 mm × 50 mm analytical column thermostated 
at 70 °C. The separations were done using 2.5 min gra-
dient method. Phase A was 0.1% formic acid in MilliQ 
water; phase B was 0.1% formic acid in acetonitrile. For 
formycins the gradient started at 5% B and increased lin-
early to 50% B in 1.6 min; at 1.8 min it returned to the 
starting condition for column equilibration. For metroni-
dazole the gradient started at 5% B and increased linearly 
to 50% B in 1.3 min; at 2.0 min it returned to the starting 
condition for column equilibration. The flow rate was 600 
μL/min in both methods. The retention time of FA was 
0.42 min, FB was 0.45 min (see Fig. 4a, b), and MTZ 
0.88 min.
MS was working in positive polarity mode, the capil-
lary voltage was 3 kV, desolvation temperature 550 °C, and 
desolvation gas flow 900 L/h. FA was analyzed using two 
transmissions 268.19 > 149.1 (Collision energy 32) and 
268.19 > 178.1 (Collision energy, CE 20); FB 269.09 > 149.1 
(CE 25) and 269.09 > 179.1 (CE 17); MTZ 172.07 > 82.00 
(CE 20) and 172.07 > 128.00 (CE 15); deuterated arginine 
180.12 > 75.07 (CE 55).
AdSS and PNP inhibition detection of cellular 
uptake
Cellular uptake of hadacidin was tested in a similar experi-
ment as FA, FB, and MTZ, but the detection method was 
different. Inhibition of AdSS was used, since the hadaci-
din molecule is too small and too volatile for the LC–MS 
approach.
AdSS catalyzes utilizing three substrates: inosine 
5′-monophoshate (IMP), guanosine 5’-triphosphate 
(GTP), and aspartate (Asp). The enzyme specific activ-
ity was determined for the purified protein, at pH 7.7, in 
20 mM Hepes/NaOH buffer at 25 °C. The reaction mix-
ture contained 0.15 mM IMP, 5 mM Asp, 0.06 mM GTP, 
and 1 mM  MgCl2 in the above-mentioned buffer. The 
reaction progress was monitored spectrophotometrically 
by adding AdSS (approximately 20 nM) to 1 mL of the 
reaction mixture (thermostated for 5 min) and by meas-
uring the change in absorption at 280 nm for 3 min. The 
extinction coefficient used to calculate the amount of 
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the products formed is ε280 = 11,700  M−1  cm−1 (forma-
tion of adenylosuccinate) (Rudolph and Fromm 1969). 
One unit (U) of AdSS enzymatic activity is defined 
as µmol of adenylosuccinate formed per min at 25 °C. 
Specific activity is expressed as units per mg of protein 
(U/mg).
For detection of cellular uptake of hadacidin, which 
is the AdSS inhibitor competing with Asp (Bubić et al. 
2018), the Asp concentration in the assay was lowered 
to 0.1 mM. Twenty microliters of each supernatant was 
added to the reaction mixture. The control reactions with 
20 μL of F12 medium (“medium”), and with 20 μL of H. 
pylori cells incubated for 8 h (“Hp cells”), were done. 
The activity observed in the latter case was treated as 
the reference, observed in the absence of the inhibitor. 
Values obtained for samples with the inhibitor in F12 
medium at the start of the accumulation test (“inhibitor_
start”) were treated as containing the starting inhibitor 
concentration (in our case 35 µM of hadacidin). Average 
activity observed for these samples was used to calcu-
late the hadacidin concentration in all other samples, in 
particular, samples incubated for 4 and 8 h at 37 °C and 
at 4 °C containing either hadacidin in F12 medium, or 
hadacidin in F12 medium and H. pylori cells (“inhibitor” 
and “Hp + inhibitor”, respectively).
Since hadacidin is an inhibitor of AdSS that competes 
with Asp, and since the Michaelis–Menten model properly 
describes the reaction (Bubić et al. 2018), the following 
equations show the dependence of initial velocity of the 
reaction on initial substrate concentration, So, observed in 
the supernatant containing only F12 medium, v (Eq. (2)), 
and containing the inhibitor, in the concentration C, in F12 
medium, vi (Eq. (3)):
where Km and Vmax are the Michaelis constant and 
maximal velocity, respectively, and Ki is the inhibition 
constant of the tested inhibitor, in our case hadacidin. At 
the start of the cellular uptake reaction Eq. (3) applies, 
and the initial velocity, vinhibitor_start , and the inhibitor 























Fig. 4  (a) Example of chromatograms of formycin A (two lower chro-
matograms) and formycin B (two upper chromatograms) obtained in 
the quantification of both compounds in the cellular uptake experi-
ments using ultra-performance liquid chromatography–tandem mass 
spectrometry, showing their retention time under conditions described 
in “Materials and methods”. (b) Two upper panels: calibration curve 
and residuals plot formycin A. Two  lower panels: calibration curve 
and residuals plot formycin B
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together with velocity measured for any tested superna-
tant, Cinhibitor_start , and velocity measured when only F12 
medium is present, v, are sufficient to determine inhibi-
tor concentration, Ctested , present in a tested supernatant, 
using Eq. (4), which is obtained by the rearrangement of 
Eq. (2) and Eq. (3):
In fact, it is not necessary to know the explicit values 
of Km, Vmax , and Ki to use this method, since none of these 


















velocity of the reaction for the sample obtained at the start 
of the experiment (“inhibitor_start”) and all other samples 
are assayed under the same conditions.
The formycin B uptake was studied in the same way, but 
instead of AdSS, PNP was used, since it is the target enzyme 
for this inhibitor. Other conditions were the following: 25 °C, 
50 mM Hepes/NaOH pH 7.0 buffer, 13 nM PNP, 50 mM 
phosphate and 60 μM  m7Guo as substrates, λobs = 260 nm, 
extinction coefficient to calculate product formation 
ε260 = 4600  M−1  cm−1 (Kulikowska et al. 1986). One unit (U) 
of PNP enzymatic activity is defined as µmol of product, in 
our case 7-methylguanine, formed per min at 25 °C. Specific 
activity is expressed as units per mg of protein (U/mg).
Fig. 5  (a) UV spectra of F12 
medium ten-fold diluted with 
water (black), and 70 µM 
water solution of formycin A 
(magenta), and formycin B 
(orange). (b) Cellular uptake of 
formycin A, and (c) formycin 
B, both at concentrations of 
350 µM, by H. pylori 26695 
strain after 8 h incubation, 
quantified by UV absorption 
spectra of ten-fold water diluted 
supernatants obtained from the 
cellular uptake experiment (see 
text for details of the method). 
F12 medium contained the fol-
lowing supplements: inhibitor 
(blue), inhibitor and H. pylori 
26695 strain (green), H. pylori 
26695 strain cells (black), 
and difference spectra (red), 
obtained by subtraction of green 
and black spectra from the blue 
(blue spectrum-green spectrum-
black spectrum), which shows 
the inhibitor uptake. Main 
figure and the respective insert 
show data obtained for samples 
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UV absorption detection of cellular uptake
For cellular uptake of formycin A and formycin B, UV absorp-
tion was additionally used as a detection method. This was pos-
sible since UV absorption of formycins is shifted to a longer 
wavelength compared with the main UV absorption bands 
of the F12 medium, exhibiting maximum of around 220 nm 
(Fig. 5a). Nevertheless, there is some overlap between these 
spectra, and because of that, selective observation of formy-
cins absorption is not possible. Moreover, during the cellular 
uptake experiment, H. pylori cells may take some UV absorb-
ing nutrients from the medium, as well as release some meta-
bolic products that also absorb in the UV region. Therefore, 
in the cellular uptake experiment, correction for absorption 
caused by these processes was introduced by including sam-
ples containing just H. pylori cells in F12 medium, incubated 
for 4 and 8 h at both temperatures, and subtracting absorption 
spectra of such supernatants. Therefore, in this case Eq. (1) 
proposed by Zhou et al. (2015) modifies to:
where C corresponds to inhibitor concentration, A, to 
the absorption of the supernatant in the chosen observation 
wavelength, and ε, to the inhibitor extinction coefficient at this 
wavelength.
Subscripts “inhibitor,” “Hp + inhibitor,” and “Hp” refer to 
blank control without cells, samples of the inhibitor incubated 
in the presence of H. pylori cells, and control with H. pylori 
cells in F12 medium, while subscripts 37 °C and 4 °C refer to 
two temperature conditions used.
Samples in this case were the same as those evaluated by 
the LC–MS detection and by analysis of the inhibition of the 
PNP activity. The UV spectra of the supernatants, from exper-
iments with 350 μM and at 35 μM inhibitor concentration, 
diluted with water 10 times and 2 times, respectively (with the 
absorbance of F12 medium, 10 times or 2 times diluted with 
water, as a reference), were measured. The absorbance at the 
most suitable wavelengths was used to calculate the formycin 
concentration. The following extinction coefficients were used: 
for FA ɛ294 = 10300  M−1  cm−1 and ɛ305 = 7100  M−1  cm−1, for 
FB ɛ279 = 7300  M−1  cm−1 and ɛ294 = 4150  M−1  cm−1. Coeffi-
cients for maxima, 294 nm for FA and 279 nm for FB, are from 
Bzowska et al. (1992), while those for 305 nm for FA and 294 
for FB were calculated on the basis of the UV spectrum of FA 
and FB in 10% F12 medium (not shown).
Statistical analysis
Data from the cellular uptake experiments were expressed as 





(Ainhibitor8h37oC − A(Hp+inhibitor)8h37oC − AHp8h37oC)
− (Ainhibitor8h4oC − A(Hp+inhibitor)8h4oC − AHp8h4oC)
]
∕
was a significant difference between the means of two groups, 
it means in supernatants incubated with and without H. pylori 
cells, and in supernatants with H. pylori incubated at 4 °C and 
in 37 °C. The GraphPad Prism program was employed to per-
form these analyses.
Results
Inhibition of H. pylori PNP by formycin B
We have previously shown that formycin A, the analogue 
of adenosine with C–C bond between the base and the 
pentose (Fig. 2), is an efficient inhibitor of purine nucleo-
side phosphorylase (PNP) from the H. pylori 26695 strain. 
The inhibition constant, Ki = 14.0 ± 1.7 μM (Narczyk et al. 
2018), is about threefold higher than that reported for E. 
coli PNP, Ki = 5.3 ± 0.4 μM (Bzowska et al. 1992). Thus, we 
decided to check another E. coli PNP inhibitor, formycin B, 
the inosine analogue with C–C bond between the base and 
the pentose (Fig. 2), vs. PNP from H. pylori 26695 strain 
(Fig. 6). We found that the inhibition constant in this case is 



















Fig. 6  Inhibition of H. pylori PNP by formycin B, at 25  °C, in 
50  mM Hepes/NaOH pH 7.0, 50  mM phosphate, with  m7Guo as a 
variable substrate. Initial velocity, vo, vs. substrate concentration is 
presented, with no inhibitor added (black circles) and with 5.33 µM 
(blue), 10.66 µM (red) and 15.99 µM (green) formycin B. Error bars 
show standard errors from two experiments. Lines show the global 
fit of the competitive inhibition model with Ki = 0.96 ± 0.08  µM, 
Km = 46.3 ± 4.4 µM, and Vmax = 12.5 ± 0.5 µmol  min−1  mg−1
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several-fold more effective inhibitor of H. pylori PNP than 
formycin A.
H. pylori sensitivity to hadacidin, formycin A, 
and formycin B
Since formycin A (FA), formycin B (FB), and hadacidin 
(Hada) are good in vitro inhibitors of H. pylori 26695 strain 
PNP and AdSS, respectively, we decided to check their 
impact on H. pylori 26695 strain growth. Although in vitro 
inhibition constants observed are Ki = 0.19 ± 0.02 μM for 
hadacidin vs. AdSS (Bubić et al. 2018), and 14.0 ± 1.7 μM 
and 0.96 ± 0.08 µM for FA (Narczyk et al. 2018) and FB vs. 
PNP, these compounds do not significantly affect growth of 
H. pylori 26695 and SS1 strains in vivo in concentrations up 
to 1000 μg/mL, which corresponds to several mM (Table 1). 
Thus, the MIC is at least orders of magnitude higher than the 
inhibition constants vs. target enzyme.
The impact of inhibitor combinations was also examined. 
This was achieved by determining the fractional inhibitory 
concentration index (FICI), according to Pillai et al. (2005), 
as described in “Materials and methods”. The data revealed 
neither synergistic nor additive effect in combination 1:1 
(w/w), with an exception of FA and FB combination against 
the strain H. pylori SS1. In this case, the effect was additive, 
as indicated by FICI = 0.62 (Table 1).
The possible reason for such a discrepancy between 
in vitro and in vivo effects could be the poor penetration of 
inhibitors into bacteria cells. Therefore, we decided to check 
cellular uptake of formycin A, formycin B, and hadacidin by 
the H. pylori 26695 strain.
Versatile method for determining cellular uptake 
of inhibitors by H. pylori
In order to check how inhibitors examined in this study 
penetrate H. pylori bacterial cells, a universal method for 
determining cellular uptake of such compounds by H. pylori 
was developed. The idea of Zhou et al. (2015), proposing a 
unique assay to measure intracellular drug penetration in 
gram-negative bacteria, was adopted for H. pylori (Fig. 3). 
Moreover, two alternative detection methods, in addition to 
the liquid chromatography (LC)–mass spectrometry (MS) 
approach exploited by Zhou et al. (2015), were shown to be 
applicable in monitoring decrease of extracellular inhibitor 
concentration as a result of inhibitor accumulation in the 
cells, which is the key idea of this method (Fig. 3).
H. pylori cells were grown in a rich medium, and centrifuged 
and resuspended in F12 minimal medium to obtain an  OD600 
of 4.0. Two samples of bacteria in the medium containing the 
tested inhibitor, at a concentration lower than its MIC value, 
were incubated, one in warm (37 °C) and the other in cold 
(4 °C) conditions. These were compared to the blanks con-
taining the same concentration of the inhibitor in F12 medium 
(without cells) at these two temperatures. The controls without 
cells at both temperature conditions documented possible sol-
vent evaporation, compound degradation, and/or nonspecific 
binding of the compound to the plates. The control with H. 
pylori cells incubated in the cold condition (4 °C) was also 
done, as it additionally accounts for a nonspecific binding 
of tested compounds to the surface of the bacterial cell wall. 
Finally, the controls with H. pylori cells in F12 medium (with-
out the inhibitor) incubated in warm and in cold conditions indi-
cate changes in the medium caused by the presence of H. pylori 
cells, which may utilize some medium components as well as 
release some products of their metabolism to the medium.
The starting concentrations of tested compounds were as 
follows: 350 μM and 35 μM for formycin A and formycin 
B, 35 μM for hadacidin, and 0.5 μM for the positive control 
compound, metronidazole. Samples were taken at the start of 
the accumulation test, and then after 4 and 8 h of incubation 
at both temperatures. The samples were centrifuged, and 
the supernatants were collected for direct measurements of 
extracellular inhibitor concentration.
Three detection methods were used to measure the 
extracellular concentration of tested inhibitors: UV absorp-
tion, proposed more than 40 years ago by Nikaido (1976); 
LC–MS, used by Zhou et al. (2015); and the inhibition of a 
target enzyme, which was our original idea, developed and 
tested in this study. Results presented below were obtained 
for the cells incubated for 8 h. In principle, similar results 
were obtained after 4 h incubation; however, since the effects 
were smaller and the errors larger, 8 h of incubation was 
better for measuring cellular uptake.
Table 1  MIC values of 
formycin A (FA), formycin B 
(FB), and hadacidin (Hada) 
against H. pylori strains. The 
results are presented as the 
geometrical mean of repetitions
Inhibitors H. pylori ATCC 26695 strain H. pylori SS1 strain
Ki (µM) MIC (µg  mL−1) MIC (mM) FICI MIC (µg  mL−1) MIC (mM) FICI
FA 14.0 ± 1.7  ≥ 870  ≥ 3.1 -  > 1000  > 3.5 -
FB 0.96 ± 0.08  > 1000  > 3.7 -  ≥ 397  ≥ 1.5 -
Hada 0.19 ± 0.02  > 1000  > 8.4 -  > 1000  > 8.4 -
FA/FB 1:1 - 500/500 1.8/1.9 1.1 177/177 0.6/0.7 0.6
FA/Hada 1:1 -  > 500/500  > 1.8/4.2  > 1.1  > 500/500  > 1.8/4.2  > 1.0
FB/Hada 1:1 -  > 500/500  > 1.9/4.2  > 1.0  > 500/500  > 1.9/4.2  > 1.8
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The differences observed for the samples of the inhibitor 
incubated with and without H. pylori cells, at cold, 4 °C, 
and warm, 37 °C, conditions, were employed to estimate 
the cellular uptake of the tested compound using Eq. (1). If 
correction for metabolites released by H. pylori was neces-
sary, Eq. (5) was used.
Extracellular inhibitor concentration quantified 
by LC–MS
Ultra-performance liquid chromatography–tandem mass 
spectrometry (LC–MS) is a very sensitive and accurate 
method to measure the extracellular inhibitor concentra-
tion. Calibration was done using the tested inhibitor, with 
the curves consisting of 6–8 points spanning the concentra-
tion range from about 10% higher than the maximal con-
centration used in the cellular uptake experiment (to capture 
the point expected when no penetration is taking place) to 
about 100-fold lower (expected in supernatant if practically 
all inhibitor penetrates the cells). Calibration samples were 
prepared by spiking blank growth medium F12 with the 
tested inhibitors, formycin A, formycin B, or metronidazole 
solutions. As internal standards, compounds that do not 
occur naturally in H. pylori were used, namely formycin A 
when analyzing formycin B, and vice versa, and deuterated 
arginine when metronidazole uptake was determined. Sam-
ples and calibrators were precipitated using internal stand-
ard solution (IS) and injected on the instrument. Calibration 
LC-MS 350 M Formycin A 
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(a) (b) 
(c) 
Fig. 7  Cellular uptake of formycin A (a) (b) and formycin B  (c) by 
the H. pylori 26695 strain after 8 h of incubation, quantified by vari-
ous methods of detection, LC–MS, UV absorbance or inhibition by 
a target enzyme, purine nucleoside phosphorylase. In the case of the 
absorbance method, shifting observation to the longer wavelength 
allowed monitoring experiments with lower inhibitor concentrations 
(here shown for 35  µM FA). Green bars show inhibitor concentra-
tion observed at the start of the incubation. Black and blue bars show 
data (extracellular inhibitor concentration) obtained for incubation at 
37 °C and 4 °C, respectively. Open bars indicate inhibitor incubated 
in the F12 medium, while filled bars indicate inhibitor incubated in 
F12 medium containing H. pylori cells. Results are mean ± SEM, 
n = 3, ****p < 0.0001; ***p < 0.001; **p < 0.01, *p < 0.05





















































































Fig. 8  Cellular uptake of formycins A and B (both at 350 µM (e) (f) 
and 35 µM (b) (c)), hadacidin (35 µM (a)) and metronidazole (0.5 µM 
(d)) by H. pylori 26695 strain after 8 h incubation, quantified by LC–
MS detection in all cases, except for hadacidin, which was quantified 
by inhibition by a target enzyme, AdSS. Black and blue bars show 
data (extracellular inhibitor concentration) obtained for incubation 
at 37  °C and 4  °C, respectively. Green bars show inhibitor concen-
tration observed at the start of the incubation. Open bars indicate 
inhibitor incubated in the F12 medium, while filled bars indicate 
inhibitor incubated in F12 medium containing H. pylori cells. Results 
are mean ± SEM, n = 3, ****p < 0.0001; ***p < 0.001; **p < 0.01, 
*p < 0.05. The intracellular accumulation of each drug was deter-
mined from these data using Eq.  (1) or Eq.  (5) as described in the 
text, and the results are shown in Table 2
Table 2  Quantification of the cellular uptake of studied inhibitors by 
H. pylori 26695 strain cells. The extracellular inhibitor concentration 
was determined by three detection methods: LC–MS, UV absorption 
spectra of the tested compounds, and inhibition of the target enzyme, 
as described in the text. The t-test was used to check for a significant 
difference in extracellular inhibitor concentration between superna-
tants incubated with and without H. pylori cells. The intracellular 
accumulation of each drug was determined using Eq.  (1) or Eq.  (5) 
as described in the text. Results of the t-test are marked as follows: 
****p < 0.0001; ***p < 0.001; **p < 0.01, *p < 0.05; ns p > 0.05, not 
significant difference
a From Bubić et al. (2018)
b From Narczyk et al. (2018)
c From Eq. (1), no correction for absorption of metabolites excreted to the medium by H. pylori was done







Metronidazole 0.5 LC–MS - 0.37 ± 0.01 ****
Hadacidin 35 AdSS inhibition - 4.9 ± 4.1 0.19 ± 0.02 vs.  AdSSa ns
Formycin A 350 UV  absorptionc 305 22.2 ± 7.6 14.0 ± 1.7 vs.  PNPb *
350 UV absorption 294 35.2 ± 7.1 **
350 LC–MS - 29.5 ± 5.3 *
35 UV absorption 305 6.7 ± 0.6 ***
35 LC–MS - 15.9 ± 0.5 ****
Formycin B 350 LC–MS - 7.1 ± 2.5 0.96 ± 0.08 vs. PNP *
350 UV absorption 279 3.0 ± 9.2 ns
350 UV absorption 294 1.0 ± 7.4 ns
350 PNP inhibition - 20.2 ± 34.0 ns
35 LC–MS - 2.5 ± 0.5 **
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curves were acquired by plotting the concentration of the 
standards against the ratio of the analyte peak area to the 
IS peak area. Correlation coefficients R2 for each standard 
curve were at least 0.99.
This detection method was used for formycins, at 35 µM 
and 350 µM concentrations, and for metronidazole at 0.5 μM 
concentration, and results are depicted in Figs. 7 and 8, and 
in Table 2. In all cases, errors of the measured concentra-
tion are very low and the uptake calculated from Eq. (1) has 
errors in the range 3–30% (see Table 2).
Despite many advantages, LC–MS is not a universal 
method, and in our research was not appropriate for hada-
cidin, as this molecule is too small and too volatile for 
LC–MS. Therefore, we developed a new detection method, 
described below.
Extracellular inhibitor concentration quantified 
by UV absorption
UV absorption in the middle- or in the near-UV region may 
be used as a detection method only for cellular uptake of 
compounds that contain UV chromophores absorbing in 
these spectral regions. Moreover, their absorption band must 
be shifted to a longer wavelength when compared with the 
main UV absorption band of the medium in which the cel-
lular uptake experiment is carried out. This method also 
requires higher dosing concentrations, due to the inherent 
insensitivity of UV absorption. Even in optimal conditions, 
the high molar extinction coefficient of the tested compound 
means that measurement of the UV absorbance will not be 
able to accurately determine concentrations lower than the 
μM range. In our case, the concentration of metronidazole 
was below the sensitivity of this detection method, and 
hadacidin did not show absorption in the appropriate UV 
region. In contrast, both formycins, in principle, fulfilled all 
the required conditions (Fig. 5a), so we used this detection 
method for each.
UV spectra of the two-fold and ten-fold diluted superna-
tants, from the cellular uptake experiments with 35 μM and 
350 μM formycin concentrations, respectively, were meas-
ured, and absorbance at 294 nm (maximum) and 305 nm in 
the case of formycin A, and 279 nm (maximum) and 294 nm 
in the case of formycin B, was used to calculate the extracel-
lular concentration of the inhibitor and its potential reduc-
tion due to uptake by H. pylori cells. One more wavelength, 
in addition to the maximum, was employed in order to lower 
the influence of UV absorption band of the F12 medium, 
partially overlapping the formycin bands (Fig. 5a).
It was noticed that during the 8 h of incubation H. pylori 
cells release some metabolic products to the medium, and 
these compounds exhibit absorption in the UV region (with 
a maximum around 260 nm, hence most probably nucleic 
acid components) as shown in Fig. 5(b, c) (black spectra). 
Therefore, correction for this absorption was necessary if 
the observation wavelength was lower than 300 nm, and it 
was done by using Eq. (5), not Eq. (1), for calculation of the 
external inhibitor concentration.
Cellular uptake determined by this detection method is 
presented in Fig. 7(a, b, c) and in Table 2. The formycin 
A spectrum overlaps less with the main UV absorption 
band of the F12 medium as compared with the spectrum of 
formycin B (Fig. 5a). Therefore, good results were obtained 
for formycin A, at both concentrations studied and for both 
wavelengths used. In contrast, for formycin B reliable results 
were obtained only for the higher concentration, 350 μM. 
The errors of the UV absorption detection method are usu-
ally higher than those of the LC–MS detection. The lowest 
obtained error was about 10% (for 35 μM of formycin A 
uptake), while only 3% for the latter method (for 35 μM of 
formycin A and for 0.5 μM of metronidazole uptake, see 
Table 2). However, when we compared the results of the 
same uptake experiments, especially when the concentration 
of the investigated compound in the cells was in the tens of 
micromoles, e.g., experiments with 350 μM of formycin A, 
errors of both detection methods were comparable.
Extracellular inhibitor concentration quantified 
by inhibition of the target enzyme
Hadacidin is too small and too volatile a molecule for the 
LC–MS approach, and its UV absorption band overlaps with 
that of the cell culture media; hence, neither of the methods 
described above could be used. Therefore, we were forced 
to develop another method to measure its concentration in 
supernatants in cellular uptake experiments. Since hadaci-
din is an inhibitor of AdSS, the concentration of hadacidin 
present in supernatant samples can be quantified by measur-
ing the ability of the supernatant to inhibit activity of this 
enzyme. Since hadacidin competes with aspartic acid, its 
concentration in the enzyme activity assay was therefore 
lowered to 0.1 mM, slightly below the Michaelis constant 
for this AdSS substrate (Bubić et al. 2018). This makes the 
activity test very sensitive to even slight changes in the con-
centration of hadacidin in the tested supernatants.
The reaction progress was monitored spectrophotometri-
cally by measuring the change in absorption at 280 nm. First, 
it was documented that the components of the F12 medium 
do not significantly affect the AdSS activity. Addition up 
to 5% of the F12 medium (50 µL in 1 mL of the reaction 
mixture) still allowed accurate measurement of the reac-
tion progress and calculation of the enzyme specific activ-
ity. If identical AdSS activities were obtained for superna-
tant taken from samples incubated at 37 °C with H. pylori 
cells, it would mean the total uptake of the inhibitor. At 
the other extreme, the appropriately lower enzyme activity 
obtained for the supernatant taken at the start of the uptake 
7962 Applied Microbiology and Biotechnology (2021) 105:7949–7967
1 3
experiment, before the cellular uptake of the inhibitor could 
start, corresponds to the starting inhibitor concentration. 
All activity values in between show some uptake, and their 
particular values were determined using Eq. [4]. No addi-
tional corrections for the inhibition by H. pylori metabolites 
excreted to the medium were necessary, since it was found 
that supernatant from samples with H. pylori 26695 after 
8 h incubation, tested in the reaction medium up to a 5% 
concentration, did not inhibit the AdSS-catalyzed reaction.
Results obtained for the uptake of 35 µM of hadacidin, 
quantified by this detection method, are shown in Fig. 8(a), 
and in Table 2.
In principle, the approach presented here is suitable for 
every possible pair of an inhibitor and its target enzyme. 
Hence, although formycin uptake was already quantified by 
the LC–MS and UV absorption, we decided to check if inhi-
bition of PNP could be used as a detection method as well.
Formycins compete with nucleosides, specifically with 
7-methylguanosine in our assay; therefore, we lowered its 
concentration in the reaction mixture to 0.05 mM, slightly 
below the Michaelis constant for this PNP substrate (Narc-
zyk et al. 2018). The reaction progress was monitored spec-
trophotometrically by measuring the change in absorption 
at 260 nm. Though the presence of the cell culture media 
F12 up to 5% in the reaction mixture does not affect PNP 
activity, H. pylori metabolites expelled to the medium do 
inhibit the PNP catalyzed reaction. Even a 2% concentra-
tion of supernatant from an H. pylori 26695 strain after 8 h 
incubation inhibited enzyme activity in the reaction medium 
22 ± 4%. Therefore, only strong inhibitors, which inhibit the 
PNP catalyzed reaction even at a low concentration (when 
a small volume of the supernatant is added to the reaction 
mixture), may be quantified for PNP. Formycin B fulfils 
this condition, as its Ki is 0.96 ± 0.08 μM. When studied 
in a 350 μM starting concentration, the respective superna-
tant present at 0.5% in the reaction medium yielded much 
stronger inhibition (activity was lowered by more than 50%) 
than the metabolites excreted by H. pylori. The resulting 
intracellular formycin B concentration determined by this 
detection method, albeit burdened with greater error, was 
consistent with results derived with the UV absorption and 
LC–MS method shown on Fig. 7(c), and in Table 2.
Cellular uptake of formycin A, formycin B, 
and hadacidin by the H. pylori 26695 strain
Cellular uptakes of formycin A, formycin B, hadacidin, 
and metronidazole by H. pylori were quantified using one 
or more detection methods, and calculated using Eq. (1) or 
(5) as described above. Metronidazole, the well-known drug 
used against H. pylori, was employed as a positive control 
of the uptake, and its concentration was 0.5 μM (80 ng/mL), 
100 times lower than its minimal inhibitory concentration 
(MIC) (according to EUCAST 2020). Since formycins and 
hadacidin, even in mM concentrations, show only moderate, 
if any, effect on H. pylori growth, their cellular uptake was 
checked at a concentration of 35 μM, which is about 100 
times lower that their estimated MIC values (Table 1), and 
in the case of formycins also in a ten-fold higher concentra-
tion, 350 μM. Results are shown on Fig. 8(a, b, c, d, e, f) and 
in Table 2.
Metronidazole, in the conditions tested, was almost com-
pletely taken inside the bacterial cells, as its intracellular 
concentration was found to be 0.37 ± 0.01 μM (Fig. 8d, dif-
ference observed for the samples with H. pylori cells, at 
cold, 4 °C, and warm, 37 °C, conditions), while the starting 
concentration was 0.5 μM. This was not the case for formy-
cin A, formycin B, and hadacidin. At 35 μM hadacidin does 
not enter H. pylori cells (Fig. 8a). For both formycins, mini-
mal uptake was observed, as intracellular amounts deter-
mined were 2.5 ± 0.5 μM for formycin B, and 15.9 ± 0.5 μM 
for formycin A (Fig. 8b, c). Moreover, the uptake was not 
significantly larger when ten-fold more inhibitor was pre-
sent. When both inhibitors were at 350 μM concentration, 
the uptake was up to 7.1 ± 2.5 μM of formycin B and up to 
29.5 ± 5.3 μM of formycin A (Fig. 8e, f, and Table 2).
Discussion
So far, loss of the de novo purine nucleotide biosynthesis 
pathway has been considered a relatively rare evolutionary 
event. However, due to the increasing number of experimen-
tal data and bioinformatic analyses now available, numerous 
examples of organisms missing enzymes for this pathway 
are known. Many represent infectious pathogenic species, 
like intracellular pathogens from the genera Chlamydia, 
Rickettsia, and Mycoplasma, and parasitic protozoans, e.g., 
Trypanosoma. As purine salvage from the environment is 
always energetically favorable when compared with de novo 
synthesis (Brault and Terjung 2001; An et al. 2008), it is 
not surprising that organisms living in purine-rich environ-
ments, like H. pylori located in the gastric mucosa, evolved 
a purine salvage pathway to meet their purine needs. Given 
the importance of purine production and its direct effect on 
viability of all cells, targeting enzymes of the purine salvage 
pathways of pathogenic organisms, for whom this meta-
bolic route is the only source of purine nucleotides, seems 
promising in the search for drugs with a new mechanism 
of action, and it has become a heavily investigated field of 
research. In the present study, we describe inhibitors of two 
purine salvage pathway enzymes, purine nucleoside phos-
phorylase (PNP) and adenylosuccinate synthetase (AdSS), 
from H. pylori, with the main goal of establishing these two 
enzymes as potential molecular targets for new drugs against 
this pathogen.
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Hadacidin (Hada), formycin A (FA), and formycin B (FB) 
(Fig. 2) inhibit H. pylori  26695 strain enzymes in vitro, with 
the following inhibition constants: 0.19 ± 0.02 μM for hada-
cidin vs. AdSS (Bubić et al. 2018), as well as 14.0 ± 1.7 μM 
for FA (Narczyk et al. 2018) and 0.96 ± 0.08 µM for FB 
vs. PNP (Fig. 6). However, in in vivo experiments, these 
compounds do not significantly affect the growth of H. 
pylori  26695 and SS1 strains (Table 1).
To see if this observed discrepancy results from a 
decreased compound penetration into H. pylori cells, we 
checked the cellular uptake of these compounds by the H. 
pylori  26695 strain. Based on the idea of Zhou et al. (2015), 
a new universal method was developed, which is suitable a 
priori for checking cellular H. pylori uptake of any possi-
ble inhibitor, with no need for isotope or fluorescent label-
ling. In this approach, the cellular uptake is quantified by 
measuring the reduction of the inhibitor concentration in the 
external culture medium, and numerous detection methods 
were shown to be suitable: LC–MS and UV absorption, as 
well as the inhibition of the target enzyme. The method has 
been confirmed using metronidazole, an antibiotic used in 
H. pylori therapies (e.g., Min Kim et al., 2020; Olmedo et al. 
2020).
Extracellular concentration of the formycins was moni-
tored by LC–MS, as described by Zhou et al. (2015), but 
it was shown that UV absorbance of these two inhibitors, 
shifted to a longer wavelength than the cell culture medium 
absorbance (Fig. 5a), may also be used to obtain results of 
essentially the same quality (Fig. 7a, b, c). However, this 
method of detection required a correction for the absorb-
ance of metabolic products released by H. pylori cells. Oth-
erwise, an apparent increase of the inhibitor concentration 
in the extracellular supernatants could be observed when 
the observation wavelength was shorter than about 300 nm 
(Fig. 5b, c). When the proper correction was done, the UV 
absorbance detection method turned out to be accurate and 
easy to perform. Additionally, it yielded results consistent 
with those obtained by the LC–MS method (Fig. 7a, b, c).
However, hadacidin is too small and too volatile to be 
detected by MS, and it exhibits UV absorption that overlaps 
with the UV absorption of the cell culture medium. Thus, 
neither of these detection methods were applicable. For this 
particular compound, we developed a new method of detec-
tion, based on the fact that hadacidin is an inhibitor of the 
AdSS enzyme. Therefore, the cellular uptake of hadacidin 
was quantified by measuring the remaining inhibition of 
AdSS by supernatant from the accumulation test (Fig. 8a). 
While the LC–MS and UV absorbance detection methods 
work quite well for the formycins, we have shown that inhi-
bition of the target enzyme, in this case PNP, may be used 
for these compounds as well.
The relative value of the correction for UV absorption 
by H. pylori metabolites is larger as the starting inhibitor 
concentration is lower; hence, the UV absorption detection 
method works better for higher inhibitor concentrations. In 
contrast, the third detection method, inhibition of the target 
enzyme activity, is more suitable for low inhibitor concen-
tration. Hence, these two methods complement each other.
Detection by the analysis of the inhibition of the target 
enzyme activity is prone to higher errors than two other 
methods. One reason for that is that the concentration of the 
inhibitor in the supernatant is inversely proportional for the 
measured parameter, enzyme activity (see Eq. (4)), while 
in two other methods, it is directly proportional (to absorb-
ance in a chosen observation wavelength in the UV absorp-
tion detection and to area under the peak in the LC–MS 
detection). Nevertheless, the standard error for inhibition of 
the target enzyme activity can be reduced by increasing the 
number of replicates, and this may be achieved by adapt-
ing the method for a microplate reader. One of the most 
prominent features of this inhibition of target enzyme activ-
ity strategy, which provides superiority over other methods, 
is that it may always be used when we know at least one 
target enzyme of the tested inhibitor. It may be an enzyme 
from a different organism than the organism for which the 
accumulation test is carried out, and it may even be an 
enzyme exhibiting a different activity that is still a target for 
the tested inhibitor. In our case, an enzyme other than PNP 
that is also inhibited by formycins could possibly be used to 
quantify cellular uptake of formycins, as PNP was found to 
be inhibited just by the metabolite products expelled by H. 
pylori cells to the incubation medium.
Our results (Table 2) show that hadacidin at 35  µM 
does not penetrate into H. pylori cells (cellular uptake of 
4.9 ± 4.1 µM), while formycin B at 350 µM and 35 µM 
exhibits minimal uptake, as the extracellular starting con-
centration of 350 µM was lowered by 7.1 ± 2.5 μM and 
2.5 ± 0.5 μM (Table 2, data from the LC–MS detection). 
For formycin A at 35 µM and 350 µM, some modest uptake 
is observed, as the corresponding decrease in the starting 
concentration was 15.9 ± 0.5 μM and 29.5 ± 5.3 μM, respec-
tively. These differences could be in some extent explained 
by the differences in hydrophobic/lipophilic properties of 
these compounds (Table 3), as some sort of correlation 
between these parameters may be noticed. At pH 7 only 
hadacidin is charged and has the lowest partition coefficient 
(− 4.06), while partition coefficients for both formycins are 
about two orders of magnitude higher, − 2.06 and − 1.90 for 
formycin B and A, respectively (Table 3). Indeed, all three 
compounds very poorly penetrate into H. pylori cells, with 
hadacidin showing the worst uptake, if any, and formycin 
A — the best from the three studied compounds. Moreover, 
good uptake of metronidazole correlates well with its rela-
tively high log P =  − 0.47 (Table 3). These data indicate that 
difference between in vitro and in vivo action of the three 
analyzed PNP/AdSS inhibitors is indeed the result of their 
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poor uptake by H. pylori cells, caused by their small parti-
tion between the lipid and aqueous phases. Therefore, one of 
possible approaches to enhance the activity of these inhibi-
tors is to combine them with compounds taken up through 
the bacterial inner membrane. This strategy requires further 
exploration.
The fractional inhibitory concentration index (FICI) was 
also measured to check if a combination of two inhibitors 
caused a synergistic or additive effect (Pillai et al., 2005). In 
the case of formycin A and B vs. SS1 strain, the FICI index 
points to an additive effect. Both compounds are inhibitors 
of PNP; hence, they compete for the same enzyme. Thus, 
this result may indicate that in H. pylori there is another 
enzymatic target for one (or both) of these compounds. This 
does not seem improbable as both are analogues of naturally 
occurring purine nucleosides (Fig. 2), adenosine and ino-
sine, respectively.
Although the three inhibitors examined in this study are 
far from being useful in clinic, the results obtained are very 
encouraging. The effects observed in vivo are very modest 
due to poor penetration of these compounds to the H. pylori 
cells, but this obstacle could probably be overcome using a 
suitable drug delivery system (e.g., see Zhang et al. (2019). 
This new method to measure cell penetration of inhibi-
tors, developed by us, will be capable of determining H. 
pylori cellular uptake of every future inhibitor designed as a 
potential drug against this pathogen. It may, in principle, be 
extended to cellular uptake by any cell type. We think that 
the detection method, based on the inhibition of the target 
enzyme of the studied compound, is especially promising 
when applied in antibiotic drug discovery, as a versatile 
solution to study the uptake measurement.
Returning to our research, it seems there is an urgent 
need to search for other PNP and AdSS inhibitors besides 
those analyzed here, to better judge the usefulness of both 
enzymes as targets for new drugs against H. pylori. Moreo-
ver, the additive effect of formycin A and B indicates that 
there is a need to analyze whether other enzymes of the 
purine salvage pathway could also serve as targets. The 
fact that the ΔdeoD mutant is incapable of growth on the 
purine base adenine hints at potential existence of an as-
yet unknown adenosine deaminase in H. pylori (Liechti and 
Goldberg 2012).
A good starting point for designing inhibitors of PNP 
and AdSS from H. pylori is the solved X-ray structure of 
the PNP complex with formycin A (Narczyk et al. 2018), 
and the recently solved structure of AdSS in a complex with 
hadacidin (to be published; PDB 6ZXQ). Such studies are 
currently in progress in our laboratories.
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